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Background. Blue light glasses have been introduced as a possible new treatment option to treat sleep disturbances in patients with
Parkinson disease (PD). Assessing patient attitudes represents a key step in the road towards formal testing and introduction into
clinical practice. Speciﬁcally, we aimed to assess how patients experience the use of blue light glasses, aiming to optimise
compliance in upcoming clinical trials where these glasses will be tested for eﬃcacy.Methods. We invited 58 PD patients who had
used the blue light glasses for at least one week on a daily basis to complete an online survey about their experiences and self-
reported impact. For this purpose, the System Usability Scale was used, supplemented with additional questions about (side)
eﬀects. A total of 31 patients (53%) replied. Results. 74% of respondents reported subjective improvements in night-time sleep,
daytime sleepiness, depressive symptoms, motor functioning, or a combination thereof.*emedian score for the SystemUsability
Scale (SUS; 0–100 range, higher scores indicating better performance) was 70.0. A total of 26 patients (84%) had an overall positive
attitude towards the technique, with patients rating the glasses with an average score of 6.9± 2.0 (SD) out of 10. Except for one
patient, all responders would like to continue using the glasses, mostly because they considered it a useful aid. Conclusion. Blue
light therapy appears to have a positive eﬀect on sleep, mood, and motor symptoms in PD. PD patients had an overall positive
attitude towards blue light glasses as treatment for sleep disorders.
1. Introduction
Parkinson’s disease (PD) is a neurodegenerative disorder
characterized by the coexistence of motor and nonmotor
symptoms [1]. Sleep disturbances are among the most
common nonmotor symptoms, occurring in up to 90% of
PD patients; these sleep disorders reduce quality of life and
hamper daytime functioning [2, 3]. Increasing evidence
suggests that one of the causes of sleep disorders is per-
turbation of the suprachiasmatic nuclei, which function as
the circadian pacemaker and are responsible for the en-
dogenous physiologic cycles occurring on approximately a
24-hour cycle [4, 5]. Light represents the most eﬀective cue
for the circadian timing system, and supplementary expo-
sure to light has beneﬁcial eﬀects on sleep quality and
daytime vigilance in healthy older people and patients with
dementia [6, 7]. In PD, the circadian system appears to have
an impact on motor and nonmotor symptoms. For example,
deterioration of motor symptoms (rigidity, tremor, and
bradykinesia) reveals abnormal circadian patterns with
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worsening throughout the day [8, 9]. Distinct diurnal os-
cillations are also observed in nonmotor symptoms in-
cluding autonomic dysfunctions, psychiatric symptoms, and
sleep impairment.*emechanisms underlying the circadian
dysfunction in PD are being increasingly unrevealed, and all
evidence clearly points towards the pathological in-
volvement of the suprachiasmatic nuclei [6, 10].
Although many diﬀerent pharmacological and non-
pharmacological strategies have been introduced to
manage sleep problems in PD, their eﬃciency remains
limited [11]. Sleep medications often result in side eﬀects
and sometimes even in worsening of PD symptoms.
*erefore, there is a great need to develop and evaluate
nonpharmacological approaches to manage not only sleep
disorders in patients but also other symptoms which are
related to the perturbation of circadian disruption. One
such treatment is bright light therapy (BLT) which is
traditionally delivered with light therapy boxes. It is
considered as a safe treatment option; only minor side
eﬀects have been reported such as headache, eye, or vision-
related complains and nausea [12]. However, light boxes
are inconvenient and force the patient to stay at one place
for at least 30minutes.
A promising new development is light therapy delivered
through light-emitting glasses, instead of traditional light
boxes. Additionally, traditional monochromatic white light
is being replaced with blue light with a wavelength ranging
from 460 to 480 nm. *is is more eﬀective in entraining the
biological clock [4] and has the potential to phase shift the
circadian output better than exposure to white light where
longer duration and higher irradiance is needed [5]. *e
glasses combine both these features as they consist of glasses
emitting blue light through integrated LED light sources
with a wavelength of approximately 468 nm and a light
intensity of 40 Lux at 1.5 cm from the eyes. As a ﬁrst step to
testing the merits of this new approach, we here assessed
eﬀectiveness and patients’ view on and attitude towards blue
light therapy glasses in real life.
2. Methods
2.1. Survey Design. *is online survey was conducted on
February and March 2018. All patients who had purchased
the blue light glasses were contacted. *ey were asked to
complete an online survey, as outlined below (Appendix 1).
*e survey included 39 questions, assessing participants’
experiences and attitudes toward blue light glasses. *e
survey included 10 items from the System Usability Scale
(SUS) [13, 14], supplemented with 22 questions about the
eﬀect of the glasses, including side eﬀects, and baseline
characteristics of the participants. Survey responses were all
anonymous. *e study was approved by the Radboudumc
ethics committee.
2.2. Study Participants and Data Collection. A total number
of 58 patients who were using the blue light glasses on a
regular basis were invited to participate in the study. *e
patients bought the glasses directly form the company
producing them (Propeaq; Chrono Eyewear BV, Tiburg, the
Netherlands) and agreed to receive research surveys in the
future. Other than having a diagnosis of PD and having used
blue light glasses for at least one week (as self-reported),
there were no formal inclusion or exclusion criteria for
participating in this survey.
2.3. Statistics. Descriptive statistics were used to summarize
all survey data collected in this study. All data are presented
as mean± standard deviation or as percentage where ap-
propriate. All data used to support the ﬁndings of this study
are available from the corresponding author upon request.
3. Results
3.1. Patients’ Characteristics. A total of 31 out of the 58
patients (53%) completed the survey (20men; 65%). Average
disease duration from PD diagnosis was 6.7± 4.6 years. Most
patients (28/31, 90%) used PD medication, mainly levodopa
preparations. Seven respondents (24%) used sleep medica-
tion, consisting of lorazepam (n� 1), alprazolam (n� 2),
clonazepam (n� 2), zopiclone (n� 1), or melatonin (n� 1).
3.2. Use of the Glasses. Most patients (23/31, 74%) used the
glasses twice daily: once in the morning and once in the
evening, for 30–60minutes each time. All other patients
used the glasses once daily in the morning expect for one
patient who used the glasses in the evening. On average,
patients had been using the glasses for 14.7± 12.1 weeks.
3.3. Eﬀects of the Glasses. Of the 31 patients, 23 patients
(74%) reported an eﬀect of the glasses. Of these, 16 patients
(70%) reported an improvement in night-time sleep, four
(13%) an improvement in daytime sleepiness, ﬁve (16%) an
improvement in depressive symptoms, and four (12%) an
improvement in motor functioning. Within the group of
participants reporting improvements, 18 (78%) used the
glasses twice daily, four (17%) once in the morning, and one
(4%) once in the evening. A similar distribution was ob-
served in those reported no eﬀect with 50% using the glasses
twice daily: 25% in the morning and 25% in the evening.
Five patients (16%) reported adverse events; one patient
reported transient cramps in her calves, and two other
patients reported transient nausea, transient tiredness,
headache, or dizziness.
3.4. System Usability Scale. All participants completed the
System Usability Scale. *e median score was 70.0 (1st and
3rd QT 57.5–80.0) which classiﬁes the glasses between “ok”
and “good” (Figure 1). For patients who noticed an eﬀect of
the glasses, the SUS score was 72.1± 14.7 (classifying them as
“good”); for the nonresponders, the SUS score was 64.1± 9.1
(classifying them as “ok”).
3.5. Usability of the Glasses. When asked, 25 patients (81%)
replied that they either agreed or strongly agreed that they
would use the glasses frequently in the future. *e other
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patients had a neutral opinion, except for one patient who
disagreed. 21 patients (68%) did not ﬁnd the glasses un-
necessarily complex, and 25 patients (81%) found the glasses
easy to use. 19 (61%) patients agreed that the glasses were not
cumbersome to use, 26 (83%) patients learned to use the glasses
themselves quickly, and 68% (21 patients) also felt conﬁdent in
using them.Only 45% (14 patients), however, indicated that the
glasses were comfortable to wear, whereas only three patients
(10%) found using the glasses a stressful event.
3.6. Attitude towards the Glasses and the Technique Used.
A total of 26 patients (74%) had an overall positive attitude
towards the technique. Overall, patients rated the glasses
with an average grade of 6.9± 2.0, and except for four pa-
tients, all patients would continue to use the glasses, mostly
because they considered it a useful aid. For patients who
noticed an eﬀect of the glasses, the grade given was 7.5± 2.5;
for the nonresponders, this was 5.4± 2.2. 26 patients (84%)
would recommend the glasses to other patients.
4. Discussion
*is was a study on feasibility and patient experiences and
not an eﬀectiveness study. Most participants reported that
the blue light glasses were acceptable and the attitude to-
wards the technique used in the device was overall positive.
Participants reported only minor side eﬀects, and nearly all
patients would continue to use the glasses for personal
beneﬁt and the sense of contributing to science. In a merely
exploratory approach (to inform future larger studies), we
did look at some outcomes, and the results showed that 75%
of participants reported improvement of PD symptoms,
such as sleep and motor symptoms, with some noticing the
change as early as within three weeks of use. *ese ﬁndings
should be interpreted with great caution, and merely to serve
further support, our hypothesized that blue light therapy
delivered via glasses might potentially oﬀer a new approach
to overcome nonmotor symptoms in PD. To actually
demonstrate this, further adequately powered trials with
blue light therapy remain needed.
*e treatment of sleep problems in PD remains chal-
lenging due to side eﬀects of pharmacological treatments,
namely, sleepiness, confusion, increased rate of falls, diz-
ziness, and cognitive impairment [15–17]. Only few studies
evaluated nonpharmacological interventions, although light
therapy has been developed in PD with good results. Blue
light is evenmore eﬀective in inﬂuencing the biological clock
[4, 18] and in phase shifting of the circadian rhythm [5], and
as such represents a promising next step in light therapy.
At ﬁrst, eﬀectiveness of BLT was conﬁrmed in the
treatment of depression in seasonal aﬀective disorder [19].
*en, BLT was oﬀered as nonpharmacological also in
neurodegenerative disorder [7, 20]. In PD, BLT aims to
improve mood and sleep impairment by shifting the timing
of the circadian clock and thereby improving circadian
rhythmicity. Light represents the most eﬀective stimulus
which is attributed to its Zeitgeber function, which resets
circadian rhythmicity reﬂected in a shift in serummelatonin
concentrations [21, 22]. To date, six studies where published
with positive results on the eﬀectiveness of BLT on non-
motor symptoms of PD [23–27]. Light therapy was well
tolerated in all those studies although none of them tested
light exposure via glasses, as we did here. Likewise, in our
study, the side eﬀects were minor and included headache,
sleepiness, and eye strain [23, 24]. *e eﬃcacy of blue light
therapy in PD should, however, be conﬁrmed in randomised
controlled trials.
*e main limitation of this study is the small number of
patients responding to the survey, and the fact that the
respondents were all users, who bought the classes
themselves. Both factors may have caused a bias towards
users being more positive about the glasses. Nonetheless,
several participants in our survey reported no eﬀect of the
glasses and had an overall negative opinion of the glasses,
reducing the likelihood of bias in the results we presented
here. Moreover, the patients studied here were precisely the
ones who would be eligible to use the glasses in either future
clinical trials or in daily life. Further studies would beneﬁt
from collecting in-depth descriptive statistics and diverse
unbiased samples to further understand user opinions and
to contribute to the further development of the light
glasses.
In conclusion, clinical validation of new digital technol-
ogies, with assessment of eﬃcacy, safety, and cost-
eﬀectiveness, will be an important part of future research
eﬀorts. But understanding the attitudes of patients is par-
ticularly useful before such validation can occur and especially
prior to any widespread potential clinical implementation.
Our results show that PD patients are generally supportive of
new technologies, such as the blue light glasses.
Data Availability
*e data used to support the ﬁndings of this study are
available from the corresponding author upon request.












imaginable Poor Ok Good
Best
imaginableExcellent
Figure 1: System Usability Scale (SUS) scoring of blue light therapy glasses as rated by participants (n� 31), indicated by the black arrow.
*e median score of 70.0 indicates a good acceptability and classes the glasses between “OK” and “good,” based on the SUS classiﬁcation.
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